Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy.
A 59-year-old man with prostate cancer and pain from multiple bone metastases was treated with 1,424 MBq (38.5 mCi) rhenium-186 hydroxyethylidene diphosphonate (Re-186 HEDP). In addition, he had nonsteroidal antiandrogen, progestagen, and an analog-luteinizing hormone. Neither chemotherapy nor external-beam radiotherapy was administered. Bisphosponate therapy was stopped 4 weeks before the administration of Re-186 HEDP. The Tc-99m HMDP whole-body scan obtained 6 weeks after therapy showed the same results as before therapy. However, 1 year after therapy, a significant reduction of the mass of the metastases was visible on bone scan. The bone scan index decreased from 34 before therapy to 10 after 1 year. The patient described significant pain relief and stopped his analgesic intake 3 weeks after therapy.
Liepe
K
K
University Hospital, Department of Nuclear Medicine, Dresden, Germany. liepe@rcs.urz.tu-dresden.de
Kropp
J
J
Hliscs
R
R
Franke
W G
WG
D001859:Bone Neoplasms / Q000150:complications / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000556:secondary*; D012968:Etidronic Acid / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds; D010146:Pain / Q000532:radiotherapy*; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000473:pathology*; D011868:Radioisotopes / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012211:Rhenium / Q000627:therapeutic use*; D013669:Technetium Tc 99m Medronate / Q000031:analogs & derivatives*
D009942:Organometallic Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; C101598:rhenium-186 HEDP; C024226:technetium Tc 99m hydroxymethylene diphosphonate; D012211:Rhenium; D012968:Etidronic Acid; D013669:Technetium Tc 99m Medronate